Cue Biopharma Inc (CUE) Stock Price, Quote & News

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 949 2680

Website: www.cuebiopharma.com

Address:

40 Guest Street, Boston, United States

fantastex Dec. 27 at 2:08 PM

$CUE did they get the NASDAQ compliance extension?

0 · Reply

merlin8121 Dec. 27 at 7:10 AM

$CUE https://www.merlintrader.com/cue-cue-biopharma/

1 · Reply

topstockalerts Dec. 27 at 12:49 AM

Top Gainers PT2 $ECDA $GAUZ $PAVS $CUE $WFF

0 · Reply

fantastex Dec. 27 at 12:10 AM

$CUE to the 🌙

0 · Reply

IntraTrades Dec. 26 at 10:12 PM

$SOPA 49.18% $PAVS 40.00% $GAUZ 38.68% $CUE 35.33% $WFF 30.88%

0 · Reply

topstockalerts Dec. 26 at 9:15 PM

Top Gainers PT2 $SOPA $GAUZ $PAVS $SDOT $CUE

0 · Reply

Heretomakemoney_ Dec. 26 at 8:48 PM

$CUE

0 · Reply

fantastex Dec. 26 at 8:38 PM

$CUE 15m+ traded in two weeks (with this week having only 4 trading days). Next week will be super interesting. Monday play ▶️

0 · Reply

Heretomakemoney_ Dec. 26 at 8:15 PM

$CUE .30+ ah you can do it 🙏

0 · Reply

fantastex Dec. 26 at 7:59 PM

$CUE 26m in cash and 23m market cap lol. This is severely undervalued. This should be minimum 200m after immunoscape tech and 40% stake

0 · Reply

Cue Biopharma Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 4:02 PM EST - 8 days ago

Cue Biopharma Announces Proposed Public Offering

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 8:00 AM EST - 7 weeks ago

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Sep 29, 2025, 9:00 AM EDT - 3 months ago

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Aug 21, 2025, 8:00 AM EDT - 4 months ago

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 16, 2025, 8:00 AM EDT - 5 months ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 1, 2025, 4:05 PM EDT - 6 months ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jun 24, 2025, 4:48 PM EDT - 6 months ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

May 12, 2025, 4:05 PM EDT - 8 months ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 8 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 5, 2025, 10:00 AM EDT - 8 months ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Apr 15, 2025, 6:12 PM EDT - 9 months ago

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Apr 15, 2025, 2:00 AM EDT - 9 months ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 14, 2025, 10:23 PM EDT - 9 months ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 5:02 PM EDT - 9 months ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 31, 2025, 4:20 PM EDT - 9 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Nov 29, 2024, 4:30 PM EST - 1 year ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 1 year ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 8, 2024, 1:30 PM EST - 1 year ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 19, 2024, 8:17 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 9:43 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Feb 29, 2024, 10:00 AM EST - 1 year ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Nov 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 11, 2023, 3:32 PM EST - 2 years ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Aug 9, 2023, 10:23 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Investor Call

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2023, 4:35 PM EDT - 2 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 8, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Mar 21, 2023, 11:00 PM EDT - 3 years ago

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

fantastex Dec. 27 at 2:08 PM

$CUE did they get the NASDAQ compliance extension?

0 · Reply

merlin8121 Dec. 27 at 7:10 AM

$CUE https://www.merlintrader.com/cue-cue-biopharma/

1 · Reply

topstockalerts Dec. 27 at 12:49 AM

Top Gainers PT2 $ECDA $GAUZ $PAVS $CUE $WFF

0 · Reply

fantastex Dec. 27 at 12:10 AM

$CUE to the 🌙

0 · Reply

IntraTrades Dec. 26 at 10:12 PM

$SOPA 49.18% $PAVS 40.00% $GAUZ 38.68% $CUE 35.33% $WFF 30.88%

0 · Reply

topstockalerts Dec. 26 at 9:15 PM

Top Gainers PT2 $SOPA $GAUZ $PAVS $SDOT $CUE

0 · Reply

Heretomakemoney_ Dec. 26 at 8:48 PM

$CUE

0 · Reply

fantastex Dec. 26 at 8:38 PM

$CUE 15m+ traded in two weeks (with this week having only 4 trading days). Next week will be super interesting. Monday play ▶️

0 · Reply

Heretomakemoney_ Dec. 26 at 8:15 PM

$CUE .30+ ah you can do it 🙏

0 · Reply

fantastex Dec. 26 at 7:59 PM

$CUE 26m in cash and 23m market cap lol. This is severely undervalued. This should be minimum 200m after immunoscape tech and 40% stake

0 · Reply

fantastex Dec. 26 at 6:03 PM

$CUE 0.35 next week then 0.40

0 · Reply

11__11 Dec. 26 at 5:38 PM

$CUE thing looks 🔥🔥🔥🔥🔥

1 · Reply

11__11 Dec. 26 at 5:27 PM

$CUE !

0 · Reply

fantastex Dec. 26 at 4:12 PM

$CUE strong

0 · Reply

DARKP00L Dec. 26 at 4:06 PM

$CUE this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

fantastex Dec. 25 at 7:40 PM

$CUE expecting 10X from this level.

0 · Reply

ConsumerAnalyst Dec. 25 at 3:26 PM

$CUE Investors are recalibrating expectations as the balance shifts from vision to execution. Sequential improvement must start appearing across core metrics. Unexpected delays could weigh disproportionately on sentiment. The thesis improves only as operational proof accumulates.

0 · Reply

fantastex Dec. 23 at 7:03 PM

$CUE barcoding. Waiting for News 100% for a 200% move up.

0 · Reply

HeavyStockHitter Dec. 23 at 12:38 AM

$CUE You people hoping and praying this stock magically rockets are completely clueless to the degenerates and pieces of shit that now are invested in your company. It is clear management is clueless on how to manage the capital markets because if they had any idea they would have sold themselves on a street corner for money before turning over the deal to the "investors" that are now involved. Dont believe me, think I am full of it, think I am some random troll? Cool. You will see. Whatever you think will happen here, it won't, now. Sorry.

3 · Reply

fantastex Dec. 22 at 7:57 PM

$CUE in 3 trading days 10m volume. It's gonna be interesting the next ones

0 · Reply

Scam_Inspector Dec. 22 at 5:37 PM

$CUE Offering expected to close today, but volume since is nowhere near enough.

1 · Reply

BigErvy Dec. 22 at 2:49 AM

$CUE No DLTS. The drop out rates tend to be low when this happens. When the drop out rates are low patients usually believe the cure is much better than any side effects. Stock is cheap because they aren't far enough along with more conclusive data. That could change fast. Could get interesting when they release data next year.

0 · Reply

Market Cap	18.98M
Revenue (ttm)	9.29M
Net Income (ttm)	-40.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-437.78%
Debt to Equity Ratio	0.12

Volume	7,139,500
Avg Vol	622,306
Day's Range	N/A - N/A
Shares Out	78.74M
Stochastic %K	35%
Beta	1.39
Analysts	Strong Sell
Price Target	$4.00